Restricted accessResearch articleFirst published online 2021-8
Recommendations for lipid modification in patients with ischemic stroke or transient ischemic attack: A clinical guide by the Hellenic Stroke Organization and the Hellenic Atherosclerosis Society
This document presents the consensus recommendations of the Hellenic Stroke Organization and the Hellenic Atherosclerosis Society for lipid modification in patients with ischemic stroke or transient ischemic attack. This clinical guide summarizes the current literature on lipid management and can be of assistance to the physicians treating stroke patients in clinical practice.
VemmosKNBotsMLTsibourisPK, et al.Stroke incidence and case fatality in southern Greece: the Arcadia stroke registry. Stroke1999; 30: 363–370.
2.
VemmosKNTakisCEGeorgilisK, et al.The Athens stroke registry: results of a five-year hospital-based study. Cerebrovasc Dis2000; 10: 133–141.
3.
StegPGBhattDLWilsonPW, et al.One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA2007; 297: 1197–1206.
4.
Luengo-FernandezRViolatoMCandioPLealJ. Economic burden of stroke across Europe: a population-based cost analysis. Eur Stroke J2020; 5: 17–25.
5.
GuyattGGuttermanDBaumannMH, et al.Grading strength of recommendations and quality of evidence in clinical guidelines: report from an American college of chest physicians task force. Chest2006; 129: 174–181.
6.
PapanagiotouPNtaiosGPapavasileiouV. Recommendations for mechanical thrombectomy in patients with acute ischemic stroke: a clinical guide by the Hellenic Stroke Organization. Clin Neuroradiol2018; 28: 145–151.
7.
PapanagiotouPNtaiosGPapavasileiouV, et al.Recommendations for mechanical thrombectomy in patients with acute ischemic stroke: a clinical guide by the Hellenic Stroke Organization. Clin Neuroradiol2018; 28: 145–151.
8.
NtaiosGAGArnaoutoglouEVavuranakisE, et al.Recommendations of the Hellenic Stroke Organization about antithrombotic management of patients with ischemic stroke. Hellenic J Atheroscler2017; 8: 5–22.
9.
SacksFMLichtensteinAHWuJHY, et al.Dietary fats and cardiovascular disease: a presidential advisory from the American Heart Association. Circulation2017; 136: e1–e23.
10.
Guasch-FerréMLiuGLiY, et al.Olive oil consumption and cardiovascular risk in U.S. adults. J Am Coll Cardiol2020; 75: 1729–1739.
11.
Guasch-FerréMHuFBMartínez-GonzálezMA, et al.Olive oil intake and risk of cardiovascular disease and mortality in the PREDIMED study. BMC Med2014; 12: 78.
12.
ReesKTakedaAMartinN, et al.Mediterranean-style diet for the primary and secondary prevention of cardiovascular disease. Cochrane Database Syst Rev2019; 3: CD009825.
13.
GrossoGMarventanoSYangJ, et al.A comprehensive meta-analysis on evidence of Mediterranean diet and cardiovascular disease: are individual components equal?. Crit Rev Food Sci Nutr2017; 57: 3218–3232.
14.
ChenGCNeelakantanNMartín-CalvoN, et al.Adherence to the Mediterranean diet and risk of stroke and stroke subtypes. Eur J Epidemiol2019; 34: 337–349.
15.
HeFJMacGregorGA. How far should salt intake be reduced?. Hypertension2003; 42: 1093–1099.
16.
ShahRSColeJW. Smoking and stroke: the more you smoke the more you stroke. Expert Rev Cardiovasc Ther2010; 8: 917–932.
17.
EpsteinKAViscoliCMSpenceJD, et al.Smoking cessation and outcome after ischemic stroke or TIA. Neurology2017; 89: 1723–1729.
18.
XingYYangSDDongFWangMMFengYSZhangF. The beneficial role of early exercise training following stroke and possible mechanisms. Life Sci2018; 198: 32–37.
19.
RimmerJHRauworthAEWangECNicolaTLHillB. A preliminary study to examine the effects of aerobic and therapeutic (nonaerobic) exercise on cardiorespiratory fitness and coronary risk reduction in stroke survivors. Arch Phys Med Rehabil2009; 90: 407–412.
20.
MillwoodIYWaltersRGMeiXW, et al.Conventional and genetic evidence on alcohol and vascular disease aetiology: a prospective study of 500 000 men and women in China. Lancet2019; 393: 1831–1842.
21.
Heart Protection Study Collaborative Group. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet2002; 360: 7–22.
22.
CollinsRArmitageJParishSSleightPPetoR. Heart Protection Study Collaborative Group. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet2004; 363: 757–767.
23.
HosomiNNagaiYKohriyamaT, et al.The Japan statin treatment against recurrent stroke (J-STARS): a multicenter, randomized, open-label, parallel-group study. EBioMedicine2015; 2: 1071–1078.
24.
AmarencoPBogousslavskyJCallahanA3rd, et al.High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med2006; 355: 549–559.
25.
AmarencoPBenaventeOGoldsteinLB, et al.Results of the stroke prevention by aggressive reduction in cholesterol levels (SPARCL) trial by stroke subtypes. Stroke2009; 40: 1405–1409.
26.
AmarencoPKimJSLabreucheJ, et al.A comparison of two LDL cholesterol targets after ischemic stroke. N Engl J Med2020; 382: 9.
27.
AmarencoPKimJSLabreucheJ, et al.Benefit of targeting a LDL (low-density lipoprotein) cholesterol < 70 mg/dL during 5 years after ischemic stroke. Stroke2020; 51: 1231–1239.
28.
TramacereIBoncoraglioGBBanziR, et al.Comparison of statins for secondary prevention in patients with ischemic stroke or transient ischemic attack: a systematic review and network meta-analysis. BMC Med2019; 17: 67.
29.
NtaiosGPapavasileiouVMakaritsisK, et al.Statin treatment is associated with improved prognosis in patients with AF-related stroke. Int J Cardiol2014; 177: 129–133.
30.
HaydenDTHannonNCallalyE, et al.Rates and determinants of 5-year outcomes after atrial fibrillation-related stroke: a population study. Stroke2015; 46: 3488–3493.
31.
ChoiJYSeoWKKangSH, et al.Statins improve survival in patients with cardioembolic stroke. Stroke2014; 45: 1849–1852.
NtaiosGPapavasileiouVMilionisH, et al.Embolic strokes of undetermined source in the Athens Stroke Registry: an outcome analysis. Stroke2015; 46: 2087–2093.
34.
MilionisHNtaiosGKorompokiEVemmosKMichelP. Statin-based therapy for primary and secondary prevention of ischemic stroke: a meta-analysis and critical overview. Int J Stroke2020; 15: 377–384.
35.
CannonCPBlazingMAGiuglianoRP, et al.Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med2015; 372: 2387–2397.
36.
BohulaEAWiviottSDGiuglianoRP, et al.Prevention of stroke with the addition of ezetimibe to statin therapy in patients with acute coronary syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation2017; 136: 2440–2450.
37.
SabatineMSGiuglianoRPKeechAC, et al.Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med2017; 376: 1713–1722.
38.
GiuglianoRPPedersenTRSaverJL, et al.Stroke prevention with the PCSK9 (proprotein convertase subtilisin–Kexin type 9) inhibitor evolocumab added to statin in high-risk patients with stable atherosclerosis. Stroke2020; 51: 1546–1554.
39.
GiuglianoRPPedersenTRParkJG, et al.Clinical efficacy and safety of achieving very low ldl-cholesterol concentrations with the pcsk9 inhibitor evolocumab: a prespecified secondary analysis of the fourier trial. Lancet2017; 390: 1962–1971.
40.
SchwartzGGStegPGSzarekM, et al.Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med2018; 379: 2097–2107.
41.
JukemaJWZijlstraLEBhattDL, et al.Effect of alirocumab on stroke in odyssey outcomes. Circulation2019; 140: 2054–2062.
42.
SalvatoreTMorgantiRMarchioliRDe CaterinaR. Cholesterol lowering and stroke: no longer room for pleiotropic effects of statins—confirmation from PCSK9 inhibitor studies. Am J Med2020; 133: 95–99.e6.
43.
BernsteinR. Uncommon causes of stroke. Arch Neurol2002; 59: 1492–1492.
44.
MarkusHSHayterELeviCFeldmanAVenablesGNorrisJ. CADISS trial investigators. Antiplatelet treatment compared with anticoagulation treatment for cervical artery dissection (CADISS): a randomised trial. Lancet Neurol2015; 14: 361–367.
45.
NtaiosGPapavasileiouVSagrisD, et al.Closure of patent foramen ovale versus medical therapy in patients with cryptogenic stroke or transient ischemic attack: updated systematic review and meta-analysis. Stroke2018; 49: 412–418.
46.
Authors/Task Force Members; ESC Committee for Practice Guidelines (CPG); ESC National Cardiac Societies. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Atherosclerosis2019; 290: 140–205.
47.
BruckertEHayemGDejagerSYauCBégaudB. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients—the PRIMO study. Cardiovasc Drugs Ther2005; 19: 403–414.
48.
CohenJDBrintonEAItoMKJacobsonTA. Understanding statin use in America and gaps in patient education (USAGE): an internet-based survey of 10,138 current and former statin users. J Clin Lipidol2012; 6: 208–215.
49.
StroesESThompsonPDCorsiniA, et al.Statin-associated muscle symptoms: impact on statin therapy–European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur Heart J2015; 36: 1012–1022.
50.
MammenAL. Statin-associated autoimmune myopathy. N Engl J Med2016; 374: 664–669.
51.
BaysHCohenDEChalasaniNHarrisonSA. The National Lipid Association's Statin Safety Task Force. An assessment by the Statin Liver Safety Task Force: 2014 update. J Clin Lipidol2014; 8: S47–S57.
52.
ChalasaniNAljadheyHKestersonJMurrayMDHallSD. Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. Gastroenterology2004; 126: 1287–1292.
53.
ChawlaJ. Stepwise approach to myopathy in systemic disease. Front Neurol2011; 2: 49.
54.
BanachMPattiAMGiglioRV, et al.The role of nutraceuticals in statin intolerant patients. J Am Coll Cardiol2018; 72: 96–118.
55.
Cholesterol Treatment Trialists' Collaboration. Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials. Lancet2019; 393: 407–415.
56.
BennMNordestgaardBGFrikke-SchmidtRTybjærg-HansenA. Low LDL cholesterol, PCSK9 and HMGCR genetic variation, and risk of Alzheimer's disease and Parkinson's disease: Mendelian randomisation study. BMJ2017; 357: j1648.
57.
GiuglianoRPMachFZavitzK, et al.EBBINGHAUS Investigators. Cognitive function in a randomized trial of evolocumab. N Engl J Med2017; 377: 633–643.
58.
ChungPWYoonBWLeeYB, et al.Medication adherence of statin users after acute ischemic stroke. Eur Neurol2018; 80: 106–114.
59.
BaigentCBlackwellL, et al.Cholesterol Treatment Trialists' (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet2010; 376: 1670–1681.
60.
HackamDGWoodwardMNewbyLK, et al.Statins and intracerebral hemorrhage: collaborative systematic review and meta-analysis. Circulation2011; 124: 2233–2242.
61.
GuedeneyPGiustinoGSorrentinoS, et al.Efficacy and safety of alirocumab and evolocumab: a systematic review and meta-analysis of randomized controlled trials. Eur Heart J2019; ehz430: 1–9.
62.
NtaiosGMichelP. Temporal distribution and magnitude of the vulnerability period around stroke depend on stroke subtype. Cerebrovasc Dis2011; 32: 246–253.
63.
KleinLW. Atherosclerosis regression, vascular remodeling, and plaque stabilization. J Am Coll Cardiol2007; 49: 271–273.
64.
MilionisHJGiannopoulosSKosmidouM, et al.Statin therapy after first stroke reduces 10-year stroke recurrence and improves survival. Neurology2009; 72: 1816–1822.
65.
YoshimuraSUchidaKDaimonTTakashimaRKimuraKMorimotoT. ASSORT Trial Investigator. Randomized controlled trial of early versus delayed statin therapy in patients with acute ischemic stroke: ASSORT trial (Administration of Statin on Acute Ischemic Stroke Patient). Stroke2017; 48: 3057–3063.
66.
FlintACConellCRenX, et al.Statin adherence is associated with reduced recurrent stroke risk in patients with or without atrial fibrillation. Stroke2017; 48: 1788–1794.
